This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer's Second Biosimilar of Remicade Receives FDA Approval
by Zacks Equity Research
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Roche/AbbVie Report Positive Phase III Results on Venclexta
by Zacks Equity Research
Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).
Novartis Announces Positive Data on Sickle Cell Disease Drug
by Zacks Equity Research
Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.
Roche Reports Positive Data from Tecentriq Combination Study
by Zacks Equity Research
Roche reported positive data from a combination study of Tecentriq and Avastin in metastatic renal cell carcinoma patients.
Foreign Stock Roundup: Bank of Montreal Q4 Earnings Decline, Rio Tinto Lowers '17 Capital Spending Target
by Swarup Gupta
Investors in Europe remained focused on Brexit negotiations and the Senate's decision to approve a new tax Bill last week.
Puma (PBYI) Stock Up More than 200% This Year: Here's Why
by Zacks Equity Research
Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.
Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz
by Arpita Dutt
FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.
Roche Reports Tecentriq/Avastin Lung Cancer Study Data
by Zacks Equity Research
Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
by Zacks Equity Research
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Roche's Avastin Gets Full FDA Approval for Brain Cancer
by Zacks Equity Research
Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.
AbbVie/J&J's Imbruvica Succeeds in Combo Study with Rituxan
by Zacks Equity Research
AbbVie (ABBV) J&J's combination study evaluating Imbruvica in Waldenstrom's macroglobulinemia (WM), a rare form of non-Hodgkin's lymphoma, meets primary endpoint.
Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest
by Zacks Equity Research
Mylan (MYL) receives approval for its biosimilar of breast cancer drug, Herceptin. Amazon is reportedly in talks with Mylan and another generic manufacturer about a potential entry in distribution of drugs.
Cancer Space Update: Pfizer's Bavencio Fails in Phase III
by Zacks Equity Research
The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.
AbbVie Stock Up More Than 30% So Far in 2H17: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained 32.1% so far in the second half of the year supported by a series of positive news in the past few months.
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
by Zacks Equity Research
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
Biogen Acquires Worldwide License for Alkermes' MS Candidate
by Zacks Equity Research
Biogen (BIIB) and Alkermes clinch collaboration agreement to develop and commercialize Alkermes' multiple sclerosis candidate, ALKS8700.
AstraZeneca Files for Label Expansion of Tagrisso in Japan
by Zacks Equity Research
AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.
Top Stock Reports for Estee Lauder, Broadcom & General Dynamics
by Zacks Equity Research
Today's Research Daily features new research reports on 16 major stocks, including Estee Lauder (EL), Broadcom (AVGO) and General Dynamics (GD).
Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up in the year so far on rapid pipeline progress plus positive study data and strategic collaborations.
Foreign Stock Roundup: BP Buys Cairn Energy Stake, Honda to Recall 900K Minivans
by Swarup Gupta
Investors across the world should brace for a volatile end to the month of November.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, GlaxoSmithKline and Roche
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, GlaxoSmithKline and Roche
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU
by Zacks Equity Research
This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.
Will New Drug Approvals Boost Novartis (NVS) Portfolio?
by Zacks Equity Research
Novartis (NVS) is facing stiff generic competition for key drugs. Nevertheless, we expect approval of new drugs to boost its portfolio.
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data
by Arpita Dutt
Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.
Puma Inks License Deal to Commercialize Cancer Drug Nerlynx
by Zacks Equity Research
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.